These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Sept. 19 through Sept. 25, 2024. Source: VerityData
Original Filings
Bicara Therapeutics RA Capital Management disclosed a new position in the clinical-stage biopharmaceutical company of 6,955,993 shares. RA Capital Management reported that it purchased 1,833,000 of those shares for $18 apiece in connection with the company's initial public offering on Sept. 16. RA Capital also entered into a lockup agreement that same day, which prohibits the sale of Bicara shares for a 180-day period following the IPO date. After the purchases, RA Capital now owns 12.8% of Bicara's outstanding stock.
Increases in Holdings
Adecoagro Tether Holdings raised its stake in the agricultural company to 13,730,453 shares. Tether Holdings purchased 1,883,704 Adecoagro shares from Sept. 12 through Sept. 20 at prices ranging from $11.06 to $11.58 each. Tether revealed an initial stake of 10,048,249 Adecoagro shares, which it purchased from July 29 through Aug. 16 at prices ranging from $9.45 to $11.66 each, and an additional 1,798,500 shares purchased from Sept. 3 through Sept. 11 at prices ranging from $11.02 to $11.42.
Following the purchases, Tether continues to own a 13.4% stake in Adecoagro.
Decreases in Holdings
Herc Holdings Gamco Investors lowered its stake in the equipment-rental firm to 1,978,083 shares. Gamco did so through the sale of 54,865 Herc Holdings shares from July 19 through Sept. 18 at prices ranging from $125.45 to $158.25 each. Following the latest sales, Gamco continues to own 7% of Herc Holdings' outstanding stock. Shares of Herc Holdings have gained about 7% year to date.
GeneDx Holdings OPKO Health reduced its stake in the genetic-testing company to 2,171,674 shares. OPKO did so through the sale of 951,729 GeneDx Holdings' shares from July 29 through Sept. 17 at prices ranging from $29.35 to $38.29 each. OPKO previously sold 435,200 GeneDx shares from July 1 through July 26 at prices ranging from $26.46 to $34.66 each.
Following the sales, OPKO continues to own 8.1% of GeneDx's outstanding stock. Shares of GeneDx have rocketed this year from $2.75 at the close of the last trading day of 2023 to a recent price of over $40. In late July, CEO Katherine Stueland said that GeneDx would reach profitability "in the next several quarters."
CBL & Associates Properties Strategic Value Partners reduced its stake in the shopping-center real estate investment trust to 1,986,637 shares. Strategic Value did so through the sale of 407,744 CBL & Associates Properties shares from Sept. 4 through Sept. 19 at prices ranging from $25.32 to $26.01 each. Following the latest sales, Strategic Value continues to own 6.3% of CBL's outstanding stock. Shares have gained about 3% year to date.
Email: editors@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
September 27, 2024 18:30 ET (22:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.